J&J’s Symtuza Approved, But Commercial Outlook Uncertain
The first HIV single-tablet regimen anchored by a protease inhibitor, Symtuza’s prospects are challenged by competitors already on the market and treatment guidelines that prefer integrase inhibitor regimens.
You may also be interested in...
Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.
ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research.
More Phase III data for Janssen's first once-daily single tablet containing four drugs for use against HIV Symtuza support its use in treatment-naïve patients; the product awaits US approval.